WU Ge-Fei,MAO Bing,HU Jia-Sheng et al. Anti-N-methyl-D-aspartate receptor encephalitis: a case report of an over 2-year-old girl[J]. CJCP, 2014, 16(4): 432-434.
WU Ge-Fei,MAO Bing,HU Jia-Sheng et al. Anti-N-methyl-D-aspartate receptor encephalitis: a case report of an over 2-year-old girl[J]. CJCP, 2014, 16(4): 432-434.
Dalmau J, Tuzun E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma[J]. Ann Neurol, 2007, 61(1): 25-36.
[2]
Taylor RB, Mason W, Kong K, et al. Reversible paraneoplastic encephalomyelitis associated with a benign ovarian teratoma[J]. Can J Neurol Sci, 1999, 26(4): 317-320.
[3]
Ances BM, Vitaliani R, Taylor RA, et al. Treatment-responsive limbic encephalitis identified by neurophil antibodies: MRI and PET correlates[J]. Brain, 2005, 128(Pt 8): 1764-1777.
[4]
Kataoka H, Dalmau J, Ueno S. Paraneoplastic encephalitis associated with ovarian teratoma and N-methyl-D-aspartate receptor antibodies[J]. Eur J Neurol, 2008, 15(1): e5-e6.
[5]
Seki M, Suzuki S, Iizuka T, et al. Neurological response to early removal of ovarian teratoma in anti-NMDAr encephalitis[J]. J Neurol Neurosurg Psychiatry, 2008, 79(3): 324-326.
[6]
Graus F, Keime-Guibert F, Rene R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients[J]. Brain, 2001, 124(Pt 6): 1138-1148.
[7]
Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia[J]. Brain, 2010, 133(9): 2734-2748.
[8]
Davies G, Irani SR, Coltart C, et al. Anti-N-methyl-D-aspartate receptor antibodies: a potentially treatable cause of encephalitis in the intensive care unit[J]. Crit Care Med, 2010, 38(2): 679-682.
[9]
Gable MS, Sheriff H, Dalmau J, et al. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project[J]. Clin Infect Dis, 2012, 54(7): 899-904.
[10]
Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis[J]. Lancet Neurol, 2011, 10(1): 63-74.
[11]
Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study[J]. Lancet Neurol, 2013, 12(2): 157-165.
[12]
Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents[J]. Ann Neurol, 2009, 66(1): 11-18.
[13]
Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies[J]. Lancet Neurol, 2008, 7(12): 1091-1098.
Luca N, Daengsuwan T, Dalmau J, et al. Anti-N-methyl-Daspartate receptor encephalitis: a newly recognized inflammatory brain disease in children[J]. Arthritis Rheum, 2011, 63(8): 2516-2522.
[18]
Ishiura H, Matsuda S, Higashihara M, et al. Response of anti-NMDA receptor encephalitis without tumor to immunotherapy including rituximab[J]. Neurology, 2008, 71(23): 1921-1923.
[19]
Wong-Kisiel LC, Ji T, Renaud DL, et al. Response to immunotherapy in a 20-month-old boy with anti-NMDA receptor encephalitis[J]. Neurology, 2010, 74(19): 1550-1551.
